BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28150013)

  • 1. Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia.
    Orioli L; Sarti K; Van Den Neste E; Maiter D
    Ann Hematol; 2017 Apr; 96(4):685-686. PubMed ID: 28150013
    [No Abstract]   [Full Text] [Related]  

  • 2. Duvelisib for the treatment of chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
    Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IPI-145 shows promise in CLL patients.
    Cancer Discov; 2014 Feb; 4(2):136. PubMed ID: 24501284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
    Patel K; Danilov AV; Pagel JM
    Blood; 2019 Nov; 134(19):1573-1577. PubMed ID: 31554637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
    Vangapandu HV; Jain N; Gandhi V
    Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New European approval: Duvelisib - relapsed/refractory CLL and follicular lymphoma].
    Fornero L; Lamure S
    Bull Cancer; 2021 Oct; 108(10):906-907. PubMed ID: 34607678
    [No Abstract]   [Full Text] [Related]  

  • 7. Duvelisib: First Global Approval.
    Blair HA
    Drugs; 2018 Nov; 78(17):1847-1853. PubMed ID: 30430368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duvelisib: A comprehensive profile.
    Aljohar HI; Al-Abdullah E; Alzoman NZ; Darwish HW; Darwish IA
    Profiles Drug Subst Excip Relat Methodol; 2024; 49():19-40. PubMed ID: 38423708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duvelisib in haematological malignancies.
    Das M
    Lancet Oncol; 2018 Nov; 19(11):e586. PubMed ID: 30318318
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of chronic lymphocytic leukemia into B-cell acute lymphoblastic leukemia.
    Yun S; Zhang L; Patel MR; Knepper TC; Chavez JC; Pinilla-Ibarz J
    Blood; 2018 Mar; 131(11):1258-1261. PubMed ID: 29437555
    [No Abstract]   [Full Text] [Related]  

  • 12. Case of hypophysitis caused by nivolumab.
    Ishikawa M; Oashi K
    J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
    [No Abstract]   [Full Text] [Related]  

  • 13. [Purine analogs of the second generation in treatment of chronic lymphocytic leukemia].
    Rupniewska ZM; Dmoszyńska A; Roliński J
    Pol Arch Med Wewn; 1994 Apr; 91(4):302-10. PubMed ID: 8072892
    [No Abstract]   [Full Text] [Related]  

  • 14. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Headache in the Setting of Immunotherapy Treatment for Metastatic Melanoma.
    Comstock DE; Nishino M; Giardino AA
    JAMA Oncol; 2017 May; 3(5):703-704. PubMed ID: 28196215
    [No Abstract]   [Full Text] [Related]  

  • 16. [Purine analogs in chronic lymphatic leukemia].
    Ellegaard J
    Ugeskr Laeger; 1996 Nov; 158(45):6413. PubMed ID: 8992673
    [No Abstract]   [Full Text] [Related]  

  • 17. DUO delivers for duvelisib.
    Brown JR
    Blood; 2018 Dec; 132(23):2422-2424. PubMed ID: 30523122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of leukemia cutis with combination of rituximab, cladribine, and cyclophosphamide in patient with B-cell chronic lymphocytic leukemia.
    Batycka-Baran A; Baran W; Dzietczenia J; Mazur G
    Ann Hematol; 2011 Aug; 90(8):979-80. PubMed ID: 20978760
    [No Abstract]   [Full Text] [Related]  

  • 19. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-mediated hypophysitis: no place like home.
    Cooksley T; Knight T; Lindsay D; Gupta A; Ho JH; Higham C; Lorigan P; Adam S
    Clin Med (Lond); 2023 Jan; 23(1):81-84. PubMed ID: 36697002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.